EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild‐Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study ( NCCH1512 )

Shusuke Yoshikawa iD, Katsuko Kikuchi, Keiko Nozawa, Yasuko Nakai, Haruhiko Fukuda, Taro Shibata, Ryunosuke Machida iD, Tetsuya Hamaguchi, Atsuo Takashima, Sumiko Takatsuka, Tomohiro Nishina, Akihito Kawazoe und 6 weitere

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17813 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Shusuke Yoshikawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Acneiform Eruptions, Protein Kinase Inhibitors, Facial Dermatoses. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prophylactic treatment with oral minocycline or doxycycline, moisturizers, and sunscreens has been reported to be beneficial for acneiform rash (AfR) caused by epidermal growth factor receptor (EGFR) inhibitors. It is desirable to predict which patients may develop severe AfR and provide prophylactic treatment. This study aimed to evaluate the association between the worst grade of facial AfR (FAfR) after initiating therapy with EGFR inhibitors and the characteristic skin type in patients with RAS wild‐type metastatic colorectal cancer enrolled in the FAEISS study (a phase III, open‐label, randomized trial evaluating topical corticosteroids for Facial Acneiform dermatitis by EGFR Inhibitors: Stepwise rank down from potent corticosteroids). Using pretreatment photographs of the face, characteristic skin types, including enlarged pores, oiliness (greasiness), and skin color/redness, were graded on a scale of 1–3. Grade 2 or higher FAfR developed in 9.1%, 27.0%, and 45.8% of patients with enlarged pore scores of 1, 2, and 3, respectively. Patients with enlarged pores tended to have more severe FAfR ( p = 0.0216). Moreover, the disease control rate (complete remission/partial remission/stable disease) of the primary disease was seen in 59.1%, 70.6%, and 87.0% of patients with an enlarged pore score of 1, 2, and 3, respectively, showing a statistically significant trend ( p = 0.038). This study suggests that a facial skin type with a high number of enlarged pores may be a marker for predicting AfR risk due to anti‐EGFR antibody therapy and better therapeutic effects for RAS wild‐type metastatic colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAcneiform EruptionsProtein Kinase InhibitorsFacial DermatosesHumansErbB ReceptorsMaleFemaleMiddle AgedAgedSeverity of Illness IndexSkinCetuximabAdultTreatment OutcomeFace

Stichwörter der Autor:innen

acneiform rashcolorectal cancerenlarged poresepidermal growth factor receptor (EGFR)facial skin type

Substanzen

ErbB ReceptorsEGFR protein, humanCetuximabProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
  • Sendai Taihaku Dermatology Clinic, Sendai, Japan.
  • Department of Nursing, Faculty of Nursing, Mejiro University Faculty of Nursing, Iwatsuki, Japan.
  • Nakai Dermatology Clinic, Tsu, Japan.
  • Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

ORCID-Profile: Shusuke Yoshikawa, Ryunosuke Machida, Takahiro Tsushima, Toshiki Masuishi, Naoya Yamazaki

Zitieren

APA

Yoshikawa, S., Kikuchi, K., Nozawa, K., Nakai, Y., Fukuda, H., Shibata, T., Machida, R., Hamaguchi, T., Takashima, A., Takatsuka, S., Nishina, T., Kawazoe, A., Tsushima, T., Takahashi, M., Hasegawa, A., Masuishi, T., Yamazaki, N., & Kiyohara, Y. (2025). Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild‐Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study ( NCCH1512 ). The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17813

Vancouver

Yoshikawa S, Kikuchi K, Nozawa K, Nakai Y, Fukuda H, Shibata T, et al. Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild‐Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study ( NCCH1512 ). The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17813

BibTeX
@article{Yoshikawa2025,
  author = {Yoshikawa, Shusuke and Kikuchi, Katsuko and Nozawa, Keiko and Nakai, Yasuko and Fukuda, Haruhiko and Shibata, Taro and Machida, Ryunosuke and Hamaguchi, Tetsuya and Takashima, Atsuo and Takatsuka, Sumiko and Nishina, Tomohiro and Kawazoe, Akihito and Tsushima, Takahiro and Takahashi, Masanobu and Hasegawa, Akiko and Masuishi, Toshiki and Yamazaki, Naoya and Kiyohara, Yoshio},
  title = {Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild‐Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study ( NCCH1512 )},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17813}
}
Kostenlos starten →